Brief Title
Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)
Official Title
Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU)
Brief Summary
MRI-guided high intensity focused ultrasound (MRI-HIFU) has been proven to be a safe and effective method in treating uterine fibroids and also adenomyosis. However, systematic studies on the effect of this treatment on factors affecting fertility are still lacking. Also quite little is known about body's systemic response to MRI-HIFU. Thus the aim of this study is to obtain more information on the systemic response of the body to the HIFU-treatment when treating non-malignant disease as well as to study the effect of MRI-HIFU on factors affecting fertility. Women with symptomatic uterine fibroids or adenomyosis suitable for MRI-HIFU treatment are recruited to this study. The severity of symptoms will be assessed with UFS-QoL and the same questionnaire will also be used in follow-up 3, 6 and 12 months after treatment. Blood, urine and endometrium samples will be collected pre- and postoperatively and during follow-up 3, 6 and 12 months after the treatment. From these samples detailed analysis of the immunological, inflammatory and hormonal response will be performed. As this is the first study in Finland of treating uterine fibroids and adenomyosis using MRI-HIFU, also a report about the efficacy of the MRI-HIFU in treating the uterine disorders will be published, and a key tool in assessing the treatment outcome would be the UFS-QoL questionnaire. Also new methods for improving patient selection as well as treatment efficacy will be evaluated in this study.
Study Type
Interventional
Primary Outcome
Technical efficacy of HIFU for treatment of uterine fibroids as assessed by a change in the Symptom Severity Score
Condition
Uterine Fibroids
Intervention
MRI-HIFU
Study Arms / Comparison Groups
Patients treated with MRI-HIFU
Description:
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Device
Estimated Enrollment
500
Start Date
January 2016
Completion Date
December 2025
Primary Completion Date
December 2025
Eligibility Criteria
Inclusion Criteria: - BMI < 35 - Premenopausal - Uterine size <20 gw - Willingness to participate to the research - Uterine fibroids with typical symptoms - Maximum of 4 treated fibroids - Dominant fibroid >2.5cm - >50% of the fibroid is treatable Exclusion criteria - Unspecified pelvic tumours or ovarian masses, PID - Major corrective surgery to uterus (simple myomectomy excluded) - Major uterine anomalies - Unability to calculate the volume of uterine fibroids - Marked uterine calcification - Marked scarring of the lower abdomen - Suspicion of malignancy - Marked general health problem contraindicating MRI - Claustrophobia
Gender
Female
Ages
18 Years - 50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Contacts
Kirsi M Joronen, PhD, , [email protected]
Location Countries
Finland
Location Countries
Finland
Administrative Informations
NCT ID
NCT02914704
Organization ID
GYN-HIFU
Responsible Party
Sponsor
Study Sponsor
Turku University Hospital
Study Sponsor
Kirsi M Joronen, PhD, Principal Investigator, Turku University Hospital
Verification Date
April 2019